Literature DB >> 7509313

Antilisterial immunity includes specificity to listeriolysin O (LLO) and non-LLO-derived determinants.

H G Bouwer1, B L Gibbins, S Jones, D J Hinrichs.   

Abstract

Subclinical infection of BALB/c mice with virulent Listeria monocytogenes leads to the generation of Listeria-specific T-cell populations required for the expression of protective immunity. The L. monocytogenes-produced hemolysin listeriolysin O (LLO) is a virulence factor which appears to be crucial for the induction of protective antilisterial immunity. Analysis of the specificity of antilisterial cytotoxic cells from Listeria-immune BALB/c donors has shown a dominant response to an epitope corresponding to amino acids 91 to 99 of LLO. Demonstration of antilisterial T cells with specificity to non-LLO-derived epitopes has been difficult to achieve because of the requirement of LLO in facilitating escape of the bacteria to the cytoplasm of the host cell and the apparent dominance of an anti-LLO response in antilisterial immunity. In this study we show that antilisterial immunity also includes specificity to non-LLO-derived determinants. We used as an immunogen an LLO- mutant of L. monocytogenes which expresses the hemolysin perfringolysin O (PFO). The LLO- PFO+ L. monocytogenes mutant possesses invasive properties similar to those of wild-type L. monocytogenes and escape from the phagocytic vacuole because of the activity of PFO. We found that J774 target cells infected with the LLO- PFO+ L. monocytogenes mutant were lysed by antilisterial cytotoxic T cells obtained from BALB/c mice immunized with wild-type L. monocytogenes. In addition, BALB/c mice immunized with the LLO- PFO+ L. monocytogenes mutant were immune to challenge with LLO+ wild-type L. monocytogenes, a finding indicative of protective antilisterial immunity specific to Listeria-derived epitopes other than LLO. Spleen cells from BALB/c mice immunized with the LLO- PFO+ L. monocytogenes mutant adoptively transferred antilisterial protection to a subsequent challenge with wild-type L. monocytogenes. This splenocyte population also contained cytotoxic cells which lysed target cells infected with either the LLO- PFO+ L. monocytogenes mutant or wild-type LLO+ L. monocytogenes but did not lyse target cells infected with an LLO-expressing Bacillus subtilis transformant. These results establish that during the immune response to L. monocytogenes, immune splenocytes with specificity for LLO and other, non-LLO-derived epitopes develop. These non-LLO epitopes serve as targets for antilisterial cytotoxic cells and for lymphocytes which adoptively transfer antilisterial immunity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509313      PMCID: PMC186221          DOI: 10.1128/iai.62.3.1039-1045.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Expression of systemic protection and delayed-type hypersensitivity to Listeria monocytogenes is mediated by different T-cell subsets.

Authors:  J R Baldridge; R A Barry; D J Hinrichs
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

2.  The listeriolysin O gene: a chromosomal locus crucial for the virulence of Listeria monocytogenes.

Authors:  P Cossart
Journal:  Infection       Date:  1988       Impact factor: 3.553

3.  Lyt-2+ T cell-mediated protection against listeriosis. Protection correlates with phagocyte depletion but not with IFN-gamma production.

Authors:  K Lukacs; R Kurlander
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

4.  T-cell subsets in delayed-type hypersensitivity, protection, and granuloma formation in primary and secondary Listeria infection in mice: superior role of Lyt-2+ cells in acquired immunity.

Authors:  M E Mielke; S Ehlers; H Hahn
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

5.  MHC-unrestricted transfer of antilisterial immunity by freshly isolated immune CD8 spleen cells.

Authors:  K Lukacs; R J Kurlander
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

6.  Membrane damage and interleukin-1 production in murine macrophages exposed to listeriolysin O.

Authors:  H Yoshikawa; I Kawamura; M Fujita; H Tsukada; M Arakawa; M Mitsuyama
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

7.  Enhanced adoptive transfer of immunity to Listeria monocytogenes after in vitro culture of murine spleen cells with concanavalin A.

Authors:  R A Barry; D J Hinrichs
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

8.  Antigen-specific Lyt-2+ cytolytic T lymphocytes from mice infected with the intracellular bacterium Listeria monocytogenes.

Authors:  G De Libero; S H Kaufmann
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

9.  Acquired resistance to Listeria monocytogenes is mediated by Lyt-2+ T cells independently of the influx of monocytes into granulomatous lesions.

Authors:  M E Mielke; G Niedobitek; H Stein; H Hahn
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

10.  Role of hemolysin for the intracellular growth of Listeria monocytogenes.

Authors:  D A Portnoy; P S Jacks; D J Hinrichs
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  14 in total

1.  Cytotoxic-T-lymphocyte responses to epitopes of listeriolysin O and p60 following infection with Listeria monocytogenes.

Authors:  H G Bouwer; D J Hinrichs
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Stress-induced ClpP serine protease of Listeria monocytogenes is essential for induction of listeriolysin O-dependent protective immunity.

Authors:  O Gaillot; S Bregenholt; F Jaubert; J P Di Santo; P Berche
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  Antigen presentation: lysoyme, autoimmune diabetes, and Listeria--what do they have in common?

Authors:  Emil Unanue; Craig Byersdorfer; Javier Carrero; Matteo Levisetti; Scott Lovitch; Zheng Pu; Anish Suri
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response.

Authors:  H G Bouwer; H Shen; X Fan; J F Miller; R A Barry; D J Hinrichs
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

5.  The roles of IL-12 and IL-23 in CD8+ T cell-mediated immunity against Listeria monocytogenes: Insights from a DC vaccination model.

Authors:  Curtis J Henry; Jason M Grayson; Kristina L Brzoza-Lewis; Latoya M Mitchell; Marlena M Westcott; Anne S Cook; Elizabeth M Hiltbold
Journal:  Cell Immunol       Date:  2010-04-24       Impact factor: 4.868

6.  Lack of expansion of major histocompatibility complex class Ib-restricted effector cells following recovery from secondary infection with the intracellular pathogen Listeria monocytogenes.

Authors:  H G Bouwer; R A Barry; D J Hinrichs
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

7.  Elimination of the listeriolysin O-directed immune response by conservative alteration of the immunodominant listeriolysin O amino acid 91 to 99 epitope.

Authors:  H G Bouwer; M Moors; D J Hinrichs
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

8.  Characterization of Listeria monocytogenes pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O.

Authors:  S Jones; D A Portnoy
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis.

Authors:  J Hess; I Gentschev; D Miko; M Welzel; C Ladel; W Goebel; S H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

10.  Human T-cell recognition of Listeria monocytogenes: recognition of listeriolysin O by TcR alpha beta + and TcR gamma delta + T cells.

Authors:  Y Guo; H K Ziegler; S A Safley; D W Niesel; S Vaidya; G R Klimpel
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.